This ARPA-H program follows from the successful DARPA Biostasis program, which aims to extend the time for lifesaving medical treatment, often referred to as “the Golden Hour” following traumatic injury or infection, thus increasing survivability for military personnel operating in far-forward conditions with limited access to medical professionals or trauma centers. To do so, the program aims to further develop novel chemical biology approaches that reversibly and controllably slow biological systems without cold-chain to stabilize and protect their functional capacity until medical intervention is possible. Biostasis compounds were formerly tested in mouse models of bacterial infection and sub-lethal radiation injury. In this ARPA-H program, three teams submitted a single, combined proposal with the Wyss Institute overseeing experiments demonstrating that formerly identified biostasis compounds can reduce mortality of fungal infections (Wyss), endometriosis pain model (BCH), and in organ preservation/transplant (VPS).